These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 24634205)

  • 1. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
    Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
    Yokota S; Imagawa T; Mori M; Miyamae T; Aihara Y; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    Lancet; 2008 Mar; 371(9617):998-1006. PubMed ID: 18358927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
    Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
    Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis.
    Pacharapakornpong T; Vallibhakara SA; Lerkvaleekul B; Vilaiyuk S
    Rheumatol Int; 2017 Feb; 37(2):251-255. PubMed ID: 27798725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial.
    Li C; Tang X; Zhou Z; Sun L; Lu M; Zhou W; Yang S; Zheng W; Yu H; Tan W; Zhang J; Zhang Y; Kong Y; Xu J
    Clin Rheumatol; 2024 Nov; 43(11):3457-3467. PubMed ID: 39279018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan.
    Yokota S; Itoh Y; Morio T; Origasa H; Sumitomo N; Tomobe M; Tanaka K; Minota S
    Ann Rheum Dis; 2016 Sep; 75(9):1654-60. PubMed ID: 26644233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis.
    Aoki C; Inaba Y; Choe H; Kaneko U; Hara R; Miyamae T; Imagawa T; Mori M; Oba MS; Yokota S; Saito T
    J Rheumatol; 2014 Jun; 41(6):1171-7. PubMed ID: 24786929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
    Yokota S; Itoh Y; Morio T; Sumitomo N; Daimaru K; Minota S
    J Rheumatol; 2015 Apr; 42(4):712-22. PubMed ID: 25684767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
    Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Isupova EA; Kuchinskaya EM; Glebova NI; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
    Pediatr Rheumatol Online J; 2015; 13():4. PubMed ID: 25685108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
    Ruperto N; Brunner HI; Ramanan AV; Horneff G; Cuttica R; Henrickson M; Anton J; Boteanu AL; Penades IC; Minden K; Schmeling H; Hufnagel M; Weiss JE; Pardeo M; Nanda K; Roth J; Rubio-Pérez N; Hsu JC; Wimalasundera S; Wells C; Bharucha K; Douglass W; Bao M; Mallalieu NL; Martini A; Lovell D; Benedetti F;
    Rheumatology (Oxford); 2021 Oct; 60(10):4568-4580. PubMed ID: 33506875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.
    Brunner HI; Ruperto N; Ramanan AV; Horneff G; Minden K; Calvo Penades I; Alexeeva E; Cleary G; Stern SM; Kone-Paut I; Maldonado Velázquez MDR; Rabinovich CE; Remesal A; Silva CA; Nikishina I; Zucchetto M; Brockwell L; Gordon O; Nagel S; De Benedetti F;
    Rheumatology (Oxford); 2024 Sep; 63(9):2535-2546. PubMed ID: 38552315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.
    Kivitz A; Olech E; Borofsky MA; Zazueta B; Navarro-Sarabia F; Radominski SC; Merrill JT; Pacheco-Tena C; Pei J; Nasmyth-Miller C; Pope JE
    J Rheumatol; 2018 Apr; 45(4):456-464. PubMed ID: 29247149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
    Machado SH; Xavier RM
    Expert Opin Drug Saf; 2017 Apr; 16(4):493-500. PubMed ID: 28277841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.
    Genovese MC; Rubbert-Roth A; Smolen JS; Kremer J; Khraishi M; Gómez-Reino J; Sebba A; Pilson R; Williams S; Van Vollenhoven R
    J Rheumatol; 2013 Jun; 40(6):768-80. PubMed ID: 23457383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial.
    Opoka-Winiarska V; Żuber Z; Alexeeva E; Chasnyk V; Nikishina I; Dębowska G; Smolewska E
    Clin Rheumatol; 2018 Jul; 37(7):1807-1816. PubMed ID: 29654485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tocilizumab on growth impairment in systemic juvenile idiopathic arthritis with long-term corticosteroid therapy.
    Miyamae T; Yokoya S; Yamanaka H; Yokota S
    Mod Rheumatol; 2014 Jul; 24(4):567-71. PubMed ID: 24252004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of tocilizumab for the treatment of polyarticular-course juvenile idiopathic arthritis.
    Zhang X; Chen YC; Terao K
    Expert Rev Clin Pharmacol; 2017 May; 10(5):471-482. PubMed ID: 28293968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.